Agricultural waste as a sustainable source for nanoparticle synthesis and their antimicrobial properties for food preservation

Traditional agriculture from cropping to harvesting is contributing to climate change by increasing global greenhouse emissions. Circular economy approaches and biorefinery technologies based on the reuse, recycling, and remanufacturing might result in the valorization of wastes that consequently would avoid environmental pollution. Nanoparticles synthesis using bio-waste such as stems, leaves, seeds, pulp, stubble, and bagasse is considered a green approach with low energy consumption, and low-cost production. Characteristics of raw materials influence the final application of nanoparticles in edible coatings, and films. Therefore, the preparation of nanoparticles based on cellulose, pectin, metal (titanium oxide, silver, zinc oxide), or silica are considered organic, inorganic, or hybrid nanocomposites, are resulted in several benefits including shelf-life extension and broad-spectrum antimicrobial properties by its capacity to encapsulate active compounds that greatly improve food preservation. For considering agro-waste-based nanoparticles in food, challenges in homogenization and synthesis, yield, and toxicity are mainly described. Therefore, this review examines the employment of agro-industrial waste for the development of sustainable nanoparticles and their synthesis methods (top-down and bottom-up). Moreover, it discusses their incorporation and role in active edible coatings and films by highlighting their bioactive properties, mechanisms of action, and applications in food group preservation

Análisis de la expresión de CD44v5 en las membranas celulares del carcinoma escamoso de pulmón

Tesis doctoral inédita leída en la Universidad Autónoma de Madrid. Facultad de Medicina. Departamento de Medicina. Fecha de lectura: 30 de Septiembre de 200

Cardiac myosin activation with omecamtiv mecarbil in systolic heart failure

BACKGROUND The selective cardiac myosin activator omecamtiv mecarbil has been shown to improve cardiac function in patients with heart failure with a reduced ejection fraction. Its effect on cardiovascular outcomes is unknown. METHODS We randomly assigned 8256 patients (inpatients and outpatients) with symptomatic chronic heart failure and an ejection fraction of 35% or less to receive omecamtiv mecarbil (using pharmacokinetic-guided doses of 25 mg, 37.5 mg, or 50 mg twice daily) or placebo, in addition to standard heart-failure therapy. The primary outcome was a composite of a first heart-failure event (hospitalization or urgent visit for heart failure) or death from cardiovascular causes. RESULTS During a median of 21.8 months, a primary-outcome event occurred in 1523 of 4120 patients (37.0%) in the omecamtiv mecarbil group and in 1607 of 4112 patients (39.1%) in the placebo group (hazard ratio, 0.92; 95% confidence interval [CI], 0.86 to 0.99; P = 0.03). A total of 808 patients (19.6%) and 798 patients (19.4%), respectively, died from cardiovascular causes (hazard ratio, 1.01; 95% CI, 0.92 to 1.11). There was no significant difference between groups in the change from baseline on the Kansas City Cardiomyopathy Questionnaire total symptom score. At week 24, the change from baseline for the median N-terminal pro-B-type natriuretic peptide level was 10% lower in the omecamtiv mecarbil group than in the placebo group; the median cardiac troponin I level was 4 ng per liter higher. The frequency of cardiac ischemic and ventricular arrhythmia events was similar in the two groups. CONCLUSIONS Among patients with heart failure and a reduced ejection, those who received omecamtiv mecarbil had a lower incidence of a composite of a heart-failure event or death from cardiovascular causes than those who received placebo. (Funded by Amgen and others; GALACTIC-HF ClinicalTrials.gov number, NCT02929329; EudraCT number, 2016 -002299-28.)